CStone presents ASCO data for CS2009 PD-1/VEGF/CTLA-4 trispecific antibody in lung, colorectal cancer trials

• CStone presented Phase I/II data at ASCO 2026 for CS2009, a PD-1/VEGF/CTLA-4 trispecific antibody, across lung and colorectal cancers.
• Early results showed strong tumor responses in first-line NSCLC, including activity in both high and low PD-L1 groups.
• Later-line NSCLC data indicated responses in heavily pretreated patients, including those with prior immunotherapy failure, suggesting potential to address resistance.
• Colorectal cancer cohorts showed signs of activity in immunotherapy-refractory disease, with additional signals in other hard-to-treat solid tumors.
• U.S. IND clearance was obtained, with a first Phase III global registrational MRCT planned by end-2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CStone Pharmaceuticals published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260601-12178722), on June 01, 2026, and is solely responsible for the information contained therein.